The American Society of Clinical Oncology (ASCO) held its annual meeting June 3-7, 2022, in Chicago, Illinois, with the theme “Advancing Equitable Cancer Care Through Innovation.” Several thousand studies were presented at the first in-person meeting since 2019. Access to care was the theme of this year’s conference and a key focus was on strategies to expand access to clinical trials.

Among the highlights were results of the Destiny-Breast04 study, a phase-3 trial which established trastuzumab deruxtecan (T-DXd, Enhertu) as an effective treatment in patients with HER2-low metastatic breast cancer. This and other studies will be discussed in future issues of Clinical Connections.